![Richard A. Markus](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Mark E. Davis | M | - |
Dantari, Inc.
![]() Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | 2 Jahre |
Sean E. Harper | M | 61 |
Dantari, Inc.
![]() Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | - |
Pascal Touchon | M | 61 |
Dantari, Inc.
![]() Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | 2 Jahre |
Gina Knox | F | - |
Dantari, Inc.
![]() Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 4 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Richard A. Markus
- Persönliches Netzwerk